AtriCure Reports Q3 2026 Revenue Growth and Return to Profitability
AtriCure (ATRC) reported strong third-quarter results for 2026, with worldwide revenue reaching $154.5 million, a 15% increase year-over-year. The company successfully transitioned from a net loss in the prior year to a net income of $4.1 million. Growth was primarily driven by robust U.S. demand for core products such as the EnCompass Clamp and AtriClip FLEX-Mini, alongside significant expansion in the pain management segment. Despite overall growth, the company noted headwinds in its minimally invasive ablation segment due to a market shift toward pulsed field ablation (PFA) catheter therapy. Additionally, international revenue saw more modest gains of 5.8% as regional funding challenges persisted in Europe. Based on these results, AtriCure raised its full-year 2026 Adjusted EBITDA guidance, reflecting improved operational efficiency and disciplined expense management.
Topics: adjusted EBITDA net income product adoption revenue growth